Literature DB >> 21631696

Clinical utility of diffusion-weighted magnetic resonance imaging in prostate cancer.

Asim Afaq1, Dow-Mu Koh, Anwar Padhani, Nicholas van As, S Aslam Sohaib.   

Abstract

UNLABELLED: What's known on the subject? and What does the study add? This article reviews what is currently known about diffusion weighted MRI (DW-MRI) in prostate cancer. This mini-review concisely summarises, for clinical managing patients with prostate cancer, the clinical utility of diffusion weighted MRI.
OBJECTIVE: • To review the clinical utility of diffusion-weighted magnetic resonance imaging (DW-MRI) in patients with prostate cancer.
MATERIAL AND METHODS: • The current literature on prostate cancer and DW-MRI was reviewed.
RESULTS: • DW-MRI can be readily acquired on a modern scanner with a short image acquisition time and no need for i.v. contrast medium. • The image contrast is based on the diffusion of water molecules and thus reflects tissue cellularity. • There is increasing evidence that DW- MRI improves the sensitivity and specificity of prostate cancer detection as well as the identification of tumour aggressiveness. • DW-MRI is also showing substantial promise as a response biomarker for both local and metastatic disease
CONCLUSIONS: • DW-MRI is proving to be a useful adjunct to conventional T2-weighted MRI sequences. • The eventual role of DW-MRI in combination with other MRI techniques for multiparametric assessment of prostate cancer needs to be defined further.
© 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2011        PMID: 21631696     DOI: 10.1111/j.1464-410X.2011.10256.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  15 in total

1.  Exponential apparent diffusion coefficient in evaluating prostate cancer at 3 T: preliminary experience.

Authors:  Sung Y Park; Chan K Kim; Jung J Park; Byung K Park
Journal:  Br J Radiol       Date:  2015-12-10       Impact factor: 3.039

Review 2.  Value of multiparametric MRI in the work-up of prostate cancer.

Authors:  F Cornud; N B Delongchamps; P Mozer; F Beuvon; A Schull; N Muradyan; M Peyromaure
Journal:  Curr Urol Rep       Date:  2012-02       Impact factor: 3.092

3.  Two solutions for registration of ultrasound to MRI for image-guided prostate interventions.

Authors:  Mehdi Moradi; Firdaus Janoos; Andriy Fedorov; Petter Risholm; Tina Kapur; Luciant D Wolfsberger; Paul L Nguyen; Clare M Tempany; William M Wells
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2012

4.  Role of diffusion-weighted magnetic resonance imaging in prostate cancer evaluation.

Authors:  D Rinaldi; F Fiocchi; G Ligabue; G Bianchi; P Torricelli
Journal:  Radiol Med       Date:  2012-05-14       Impact factor: 3.469

5.  Multiparametric MRI appearances of primary granulomatous prostatitis.

Authors:  Su-Min Lee; Konrad Wolfe; Peter Acher; Sidath H Liyanage
Journal:  Br J Radiol       Date:  2019-04-09       Impact factor: 3.039

Review 6.  The value of diffusion-weighted imaging in the detection of prostate cancer: a meta-analysis.

Authors:  Chen Jie; Liu Rongbo; Tan Ping
Journal:  Eur Radiol       Date:  2014-05-28       Impact factor: 5.315

Review 7.  Advances in bladder cancer imaging.

Authors:  Shaista Hafeez; Robert Huddart
Journal:  BMC Med       Date:  2013-04-10       Impact factor: 8.775

8.  Prostate stereotactic body radiotherapy with simultaneous integrated boost: which is the best planning method?

Authors:  Alison Tree; Caroline Jones; Aslam Sohaib; Vincent Khoo; Nicholas van As
Journal:  Radiat Oncol       Date:  2013-10-02       Impact factor: 3.481

9.  Early experience with active surveillance in low-risk prostate cancer treated.

Authors:  Ji Yong Ha; Byung Hoon Kim; Choal Hee Park; Chun Il Kim
Journal:  Korean J Urol       Date:  2014-03-13

10.  Radiologic presentation of chronic granulomatous prostatitis mimicking locally advanced prostate adenocarcinoma.

Authors:  Su-Min Lee; Jay Joshi; Konrad Wolfe; Peter Acher; Sidath H Liyanage
Journal:  Radiol Case Rep       Date:  2016-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.